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Background: Hyperthermic isolated limb perfusion with tumor necrosis factor-α and melphalan (TM-HILP) has been
successfully used to treat limb soft tissue sarcomas (STSs) with high response rates. The data on the effectiveness of
HILP-TM for the treatment of STSs are mainly based on various STS types. The aim of this study was to investigate
the responses of synovial sarcomas (SS) to TM-HILP.
Methods: A total of 125 TM-HILP-treated tumors (STSall), including 14 SSs, were included in the study. The tumors
were subdivided into proximal and distal limb localizations. Tumor typing (using the WHO classification), resection
status (using the UICC classification), and response to therapy were assessed using light microscopy. The SSs were
tested for the SYT-SSX translocation using RT-PCR. The following tests were applied: a chi-squared test, a t test, and
the Mann-Whitney U test.
Results: The SSs were localized distally more often than were the STS cohort (STS−SS) (85.7% vs. 32.4%) and were
smaller (5.8 cm vs. 10.7 cm). There were no differences in the responder/nonresponder ratios or the mean
percentages of pathological regression between the SS and STS−SS cohorts (74.0% vs. 76.0%). A general localization-
dependent difference in the tumor responses to TM-HILP could not be detected in the STSall cohort (distal, 72.0%
vs. proximal, 78.0%); however, a UICC R0 status was more often observed in proximal tumors (distal, 50.0% vs.
proximal, 71.4%). There was no association between the SYT-SSX type and SS responses to TM-HILP.
Conclusions: Because of the high response rates, TM-HILP is recommended for the treatment of SSs. The distal
limb localization of TM-HILP-treated STSs was generally (STSall cohort) associated with fewer R0 resections.
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Soft tissue sarcomas (STSs) are members of a heteroge-
neous group of tumors that encompasses more than 50
subtypes. The majority of STSs are located in the limbs.
The mainstay of local treatment for sarcomas of the ex-
tremities is limb-sparing surgery with complete tumor
resection and clear surgical margins [1].* Correspondence: florian.grabellus@uk-essen.de
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the Creative Commons Attribution License (ht
distribution, and reproduction in any mediumHyperthermic isolated limb perfusion with tumor ne-
crosis factor-α (TNF-α) and melphalan (TM-HILP) is a
promising local treatment for locally advanced STSs,
such as nonresectable STSs of the limbs, and has
resulted in high tumor response rates and high limb sal-
vage rates [2].
STSs represent a heterogeneous group of malignancies
with different tumor biology and prognoses; however,
the pathological grading, clinical evaluation and treat-
ment of STS types follow common principles. Published
data on the effectiveness and outcomes of TM-HILP
-treated STSs are based on mixed STS cohorts:Med Central Ltd. This is an Open Access article distributed under the terms of
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represent the majority of cases. In these studies, only
sporadic histopathological regression data were obtained
after TM-HILP, and the SS regression results are
presented for only small numbers of cases and with vari-
able results (Table 1).
The aim of this study was to investigate the STS
subgroup of synovial sarcomas (SSs) and their histo-
pathological responses to TM-HILP and to compare
the results with those for the complete TM-HILP




From February 2002 to November 2012, 164 patients
with STSs (including 20 with SS) were treated with TM-
HILP at the University Hospital of Essen.
Resection specimens could be obtained from 125 (76.2%)
patients (STSall), including 14 patients with SSs, for whom
TM-HILP was performed to treat a nonresectable soft tis-
sue sarcoma manifestation.
Patients were selected for the TM-HILP program
according to the inclusion criteria outlined by Eggermont
et al. [21]. Patient evaluation and TM-HILP treatment
were exclusively performed by the same specialized team.
In brief, TM-HILP was performed under mildTable 1 Regression of SSs in other isolated limb
perfusion studies with complete histopathological
regression data
Study N Result (regression %) Valuation
[3] 24 Not specified for SS -
[4] 24 Not specified for SS -
[5] 14 Not specified for SS -
[6] 10 Not specified for SS -
[7] 9 Not specified for SS -
[8] 6 Not specified for SS -
[9] 6 Mean 66%; median 75% Modest
[10] 5 2 × >90%; 3 × 90% to 60% Modest
[11] 5 2 × 80%, 1 × 10, 35, 70% Modest
[12] 4 3 × >90%; 1 × 10 to 50% Good
[13] and [14] 4 3 × ≥50%; 1 × < 50% Modest
[15] 4 3 × 0%; 1 × 25% Poor
[16] 4 3 × ≤50%; 1 × >50% Poor
[17] 2 1 × 100%, 1 × >80% Good
[18] 2 1 × 80%; 1 × 95% Good
[19] 2 Not specified for SS -
[20] a 1 1 × >50% -
Studies with complete histopathological regression data or a report of SS
regression were included; aTM-HILP + interferon-γ.hyperthermia (39°C) and leakage monitoring with
radiolabeled serum. The administered dose of recombin-
ant human TNF-α was adjusted to 0.25 mg/l perfused tis-
sue volume (but not less than 1 mg/limb), and melphalan
(L-phenylalanine mustard) was used at concentrations of
11 mg/l for legs and 13 mg/l for arms.
All the patients provided informed consent, and the
study was performed strictly according to the Declar-
ation of Helsinki.
Gross pathology
All the specimens were fixated in 4% neutral buffered
formalin. For all the specimens, a gross estimation of
tumor necrosis was recorded and a minimum of one
block per centimeter of the largest dimension of the
tumor was collected.
Histopathology
Basic microscopic evaluation of H&E-stained slides was
performed.
Typing and grading
The STSs were typed according to the World Health
Organization (WHO) classification of tumors for STSs
and bone tumors. The STSs were graded using pri-
mary biopsies according to the French Fédération
nationale des centres de lutte contre le cancer. During
subtyping, the SSs were further divided into spindle
cell (monophasic fibrous), biphasic, and poorly differ-
entiated types [22].
Tumor regression after therapy
Total regression was assessed using light microscopy
(Figure 1) and was determined as the percentage of the
devitalized tumor after TM-HILP. Tumor regression was
graded using the six-stage grading scale of Salzer-
Kuntschik [23], and the tumors were further subdivided
into ‘responders’ (<10% viable tumor) and ‘nonre-
sponders’ (≥10% viable tumor).
Reverse transcriptase polymerase chain reaction (RT-PCR)
For RT-PCR, three or four 10-μm thick sections of tumor
tissue were transferred to microcentrifuge tubes and
deparaffinized. RNA extraction was conducted using the
RNeasy FFPE kit (QIAGEN, Hilden, Germany). For com-
plementary deoxyribonucleic acid (cDNA) synthesis, RT-
PCR was performed using M-MulV reverse transcriptase
(Fermentas, St Leon-Rot, Germany). The presence of
amplifiable mRNA was confirmed by RT-PCR using con-
trol primer sets for hypoxanthine-phosphoribosyl-trans-
ferase. The cDNA products were then subjected to gene
fusion experiments by PCR (Primers SYT-F: AGACCAA
CACAGCCTGGACCA; SSX1-R: GGTGCAGTTGTTTC
CCATCG; and SSX2-R: GGCACAGCTCTTTCCCATCA
Figure 1 Macroscopic and microscopic features of two SSs after treatment with TM-HILP. (A-C) Case number 5, nonresponder. (A) 7.9 cm
SS of the foot with a regression of 65% after TM-HILP. (B) Necrotic areas with yellow tumor changes and viable tumor residues in proximity to a
removed tendon segment (*). (C) Histopathology of a predominately viable tumor next to the cross-section of a tendon (*). The tumor infiltrates
the inked margin (arrow). (D-F) Case Number 6, responder. (D) 9.0 cm SS of the lower leg with a regression of 99%. (E) Abundant areas of yellow
necrosis mixed with glassy-white sclerotic areas after therapy. (F) Histopathology revealed only a few small foci of viable tumor (arrows). These
residues were completely removed.
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trophoresis with 2% agarose gels and ethidium bromide
staining. The DNA from SYT-SSX1- and SYT-SSX2-posi-
tive SSs served as positive controls.
Statistics
Statistical analyses were performed with IBM SPSS Sta-
tistics 19. The following tests were applied: a chi-
squared test, a t test, and the Mann-Whitney U test.
P values ≤ 0.05 were considered statistically significant.
Results
Patients
The male-to-female ratios were 6:8 for the synovial sar-
coma (SS, Table 2) cohort and 52:59 for the complete
STS cohort (STS−SS). The mean age of the SS patients
was lower than that of the STS−SS patients (45 vs. 57
years; t test, P < 0.01). The SSs were mainly primary tu-
mors (8/14, 57.1%). Five tumors were recurrences, and
one tumor was a residuum after prior surgery (STS−SS:86 primary tumors, 77.5%; 22 recurrences, 19.8%; and 3
residua, 2.7%). Moreover, the tumors in the SS cohort
were more often localized distally (proximal/distal: SS,
2/12, 85.7% vs. STS−SS, 75/36, 32.4%; chi-squared test,
P < 0.001). Distal localization was defined distally rela-
tive to the knee or elbow joint. The foot was the primary
localization of the SS cohort (5/14, 35.7%), and the thigh




The most frequent STS subtypes of the STS−SS cohort
were the undifferentiated pleomorphic sarcoma (28/111,
25.2%) and liposarcoma types (23/111, 20.7%). The
tumor grades according to the French Fédération
nationale des centres de lutte contre le cancer (three
grades: 1, 2, and 3) were 0, 8, and 6 for the SS cohort
and 7, 49, and 55 for the STS−SS cohort. Moreover, the
SSs were significantly smaller at the time of resection
Figure 2 Box plots show a comparison of the regression results
(%) between the synovial sarcomas (SS, N = 14) and the
comparison group (STS−SS, N = 111). No significant differences
were detected.
Table 2 Characteristics of the synovial sarcomas
Tumor number Age of patient Sex of patient SS type SYT-SSX fusion type Localization Size (cm) Regression (%)
1 52 Female Spindle cell SSX2 Foot 3.5 99
2 44 Male Spindle cell SSX1 Forearm 3.2 3
3 24 Female Spindle cell SSX2 Lower leg 2.5 85
4 24 Male Spindle cell SSX1 Thigh 6.2 98
5 75 Female Biphasic SSX1 Foot 7.9 65
6 29 Female Biphasic SSX2 Lower leg 9.0 99
7 38 Female Spindle cell SSX1 Thigh 16.0 20
8 65 Male Spindle cell SSX1 Foot 5.5 80
9 70 Female Biphasic SSX1 Forearm 3.5 100
10 46 Male Spindle cell SSX1 Lower leg 7.0 30
11 10 Female Poorly differentiated Wild type Foot 4.0 100
12 45 Male Biphasic SSX1 Lower leg 10.0 65
13 58 Male Spindle cell SSX1 Foot 3.0 99
14 50 Female Spindle cell SSX1 Forearm 1.2 98
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cm; Mann-Whitney U test, P = 0.004).
Regression after TM-HILP
There were 7/14 (50.0%) responders in the SS cohort
according to the Salzer-Kuntschik regression grading
scale. Two (14.3%) of those SSs exhibited complete patho-
logical regression. The STS−SS cohort included 66/111
(59.5%) responders, of which 24 (21.6%) were complete
responders. There were no differences in the responder/
nonresponder ratios (chi-squared test, P = 0.499) or in the
mean percentages of pathological regression between the
SS and STS−SS cohorts (SS, 74.0% vs. STS−SS, 76.0%;
Mann-Whitney U test, P = 0.776, Figure 2).
Because of the predominant distal localization of the
SSs in this study, we did not detect any localization-
dependent (distal/proximal) differences in the tumor
responses to TM-HILP according to the mean percentages
of pathological regression in the STSall cohort (distal,
N = 48, 72.0% vs. proximal, N = 77; 78.0%; Mann-Whitney
U test, P = 0.493).
The SYT-SSX fusion type and responses
Overall, ten SS cases were SYT-SSX1-positive and three
were SYT-SSX2-positive. In one case (see Table 1), none
of the fusions could be detected by PCR. Despite the
negative molecular pathological results for SYT-SSX1
and SYT-SSX2, this tumor was typed as SS by three sar-
coma experts at three different institutions because of its
conventional, immunohistochemical characteristics and
a borderline fluorescence in situ hybridization result.
The SSs with these genetic signatures included both
responders and nonresponders (see Table 1), and there
were no significant differences among the responses toTM-HILP. The SYT-SSX2 fusion type was exclusively
found in female patients (3/3).
Resectability
The investigation of the resection status (UICC, R classi-
fication) found 8/14 (57.1%) complete resections (R0 sta-
tus) in the SS cohort. Both complete responders (100%
pathological devitalization) in the SS group had an
R1 status. Complete resection was observed in 71/111
(64.0%) STS−SS tumors. This difference between the
groups was not statistically significant (chi-squared test,
P = 0.618). Both proximal SSs (2/2) and 6/12 of the dis-
tal SSs were completely resected, which is principally in
line with the results below, but was not significant for
Schwindenhammer et al. World Journal of Surgical Oncology 2013, 11:185 Page 5 of 7
http://www.wjso.com/content/11/1/185the SS group alone. However, the resection status results
of the proximal and distal limb localizations indicated
better resectability for proximal STSs in the STS−SS co-
hort according to the R0 status (53/71 R0 proximal,
74.6% vs. 22/40 R0 distal, 55.0%; chi-squared test,
P = 0.034). This result remained statistically significant when
the 14 SSs were included in the calculation (STSall: 55/
77, 71.4% vs. 24/48, 50.0%; chi-squared test, P = 0.016).
Discussion
The treatment of STSs is increasingly determined by the
identification of histological subtypes in a family of un-
common cancers that comprises more than 50 subtypes
[25]. Published data on the effectiveness and outcomes
of TM-HILP-treated STSs are based on studies in which
common and rare STS entities were mixed [2]. Histology
is relevant for target therapies and now for the precise
application of conventional chemotherapy regimens;
therefore, we suggest that the effect of TM-HILP on STS
subentities should be confirmed.
The frequencies and sizes of the SSs
SSs represent approximately 5% to 10% of all STSs. Be-
cause of their predominant localization within the limbs,
the frequency of SSs at limb sites has ranged from 12%
to 15% of all limb STSs [26]. The frequency of SSs in
this investigation was 11.2% in a limb STS cohort, which
is within the range of previously published data. Add-
itionally, we observed a smaller median tumor size (4.2
cm) than that reported for large SS cohorts (6 to 7 cm)
[27-30]. This finding may be a consequence of the vari-
ous tumors in this study, which included primary tu-
mors (5.5 cm) and recurrences and residual tumors after
surgery (3.7 cm).
Localization of the SSs
Most SSs are limb-based tumors. Approximately 67% to
86% of SSs arise within the extremities [27-31]. Of those
SSs, distal localization was found in 47% to 71%
[27,29,31] of cases, which is approximately twice as high
as the rates for limb STSs [32,33]. Additionally, a higher
rate was found in this study (86.7%), which is a hallmark
of isolated limb perfusion (ILP) studies.
Responses of SSs to TM-HILP
The clinical and pathological response rates of sarcomas
to TM-HILP are typically high. The mean clinical overall
response in TM-HILP studies according to the WHO
criteria [34] was initially reported to be more than 90%
with complete responses in more than 80% of cases [35].
To date, the largest studies have adjusted these clinical
data downward to an overall response rate of approxi-
mately 70% and a complete response rate of 20% [36].
Interestingly, clinical and pathological response evaluationshave often differed substantially, which we have recently
demonstrated to be the result of an insufficiency in size-
based clinical response criteria that would indicate actual
tumor responses (measured by a pathological investigation
as the gold standard) [37]. The SS cohort exhibited a mean
pathological response rate that was approximately identical
to that of the STS−SS in this cohort of resected STS. This
indicates that TM-HILP can be recommended for this STS
subtype despite the disproportionate number of distal limb
localizations.
Responses of the genetic subtypes to TM-HILP
The t(X;18) translocation, which results from the SYT-
SSX1 and SYT-SSX2 gene fusions, is found in approxi-
mately all SSs [26]. This genetic alteration has not yet
been found in any other human malignancy; therefore,
these genetic signatures have significant diagnostic value.
The impact of the SYT-SSX fusion type on the clinical
behavior of SSs is the subject of scholarly discourse with
contrasting results [28,38]. The influence of the trans-
location type on the response to treatment has not been
investigated to date but might be reflected by the prog-
nostic significance of the type according to metastatic
potential and overall survival times [38,39]. This study
did not find varying responses to TM-HILP among the
SYT-SSX translocation types in our small SS cohort.
Resectability of the SSs after TM-HILP
The mainstay of surgical treatment for STSs is limb-
sparing resection with clear surgical margins [1]. There is
disagreement regarding the size of an adequate wide surgi-
cal margin [1]. TM-HILP is indicated only for the sub-
group of STS patients who are candidates for disabling
surgery or amputation. In this study, a surgical approach
with oncological adequacy of margin width was not pos-
sible. Even after TM-HILP, the margin size and quality is
generally poor [40]. However, we have previously demon-
strated that local tumor control after TM-HILP and resec-
tion is superior compared with nonpretreated STSs, most
probably due to the strong toxic effects of TM-HILP on
the tumor periphery [3,40].
This study demonstrated a high rate of distally located
tumors (40%), which is typical for ILP-treated STS
cohorts compared with most non-ILP-treated cohorts.
Because of the specific anatomic conditions that are
found in the distal parts of the extremities, the rate of
complete resections with clear surgical margins is gener-
ally low [41]. Tumors are frequently rated as ‘primarily
unresectable’ and are possible candidates for TM-HILP
programs. Several large studies have demonstrated prox-
imal and distal localizations of STSs but only provided
the histological margin status for the complete cohort
(≈10% to 20% R1-resections) [33,42,43]. Studies that
have selectively investigated ‘distal STSs’ have not
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margins [44-48].
This study found a comparatively high rate of incom-
pletely resected tumors after TM-HILP (38.4%), which is
in agreement with results from studies in Rotterdam
[15,36]. In addition, this study found a significantly re-
duced resectability (in terms of the R0 classification) rate
in distal limb localizations [15]. Interestingly, the average
width of the margins of the R0 resected tumors did not
vary significantly according to localization and was low:
the proximal mean was 0.8 mm, and the distal mean
was 1.2 mm.
A worsening of the effectiveness of TM-HILP on dis-
tally located STSs, possibly due to impaired blood flow,
was not detected in our study. Deroose et al. [15] re-
cently investigated STSs of distal limbs and found a limb
salvage rate of 87% after TM-HILP. They stated, ‘TM-
ILP is an effective treatment modality in patients with
distal STS,’ but they found a considerably lower average
percentage of pathological regression than that in this
study (33.4% vs. 70.0%).
Conclusion
In conclusion, we found that the preoperative treat-
ment TM-HILP is as effective for the subentity of SSs
as for the complete group of STSs. Accordingly, TM-
HILP is recommended for this tumor type even though
it is often located distally. A distal localization resulted
in reduced resectability in the STSall cohort according
to the R0 rate, but the margin size of the complete re-
sections did not differ significantly between both types
of localization.
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